Show simple item record

dc.contributor.authorGorog, Diana
dc.contributor.authorGeisler, Tobias
dc.date.accessioned2020-03-12T01:04:33Z
dc.date.available2020-03-12T01:04:33Z
dc.date.issued2020-01-19
dc.identifier.citationGorog , D & Geisler , T 2020 , ' Platelet inhibition in acute coronary syndrome and PCI: Insights from the past and present ' , Thrombosis and haemostasis . https://doi.org/10.1055/s-0040-1702920
dc.identifier.issn0340-6245
dc.identifier.otherPURE: 18831483
dc.identifier.otherPURE UUID: d11f7991-7cd8-41ec-811f-f4358b7f503d
dc.identifier.otherScopus: 85083544605
dc.identifier.urihttp://hdl.handle.net/2299/22413
dc.description© 2020 Thieme Publishing Group. This is an accepted manuscript of an article accepted for publication in Thrombosis and Haemostasis.
dc.description.abstractPlatelet activation and aggregation have a pivotal role in arterial thrombosis and in the pathogenesis of both acute coronary syndromes (ACS) and in the thrombotic complications that occur in patients undergoing percutaneous coronary intervention (PCI). The last 30 years has seen the progress from early trials of clopidogrel and glycoprotein IIb/IIIa inhibitors, to the application of more potent P2Y12 inhibitors prasugrel and ticagrelor. Early enthusiasm for newer and more potent antiplatelet agents, which could reduce ischaemic events, has led to the understanding of the importance of bleeding and a desire to individualise and optimise treatment. It has increasingly become apparent that the potency and duration of dual antiplatelet therapy (DAPT) has to reflect the balance between ischaemic and bleeding risk. Recently, multiple strategies have been proposed to individualise DAPT intensity and duration, in order to reduce the bleeding and ischaemic risks. Strategies of de-escalation of DAPT intensity, as well as shorter (less than a year) or more prolonged (beyond a year) treatment have been proposed, as well as platelet function test and genotype guidance of P2Y12 inhibitor therapy. Herein, we provide an overview of the progress in the field of antiplatelet therapy for ACS and PCI over the years, showing the current directions of travel. Ongoing studies focusing on personalised antiplatelet treatment will hopefully yield further insight into ways of optimising outcomes for the individual.en
dc.language.isoeng
dc.relation.ispartofThrombosis and haemostasis
dc.titlePlatelet inhibition in acute coronary syndrome and PCI: Insights from the past and presenten
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.date.embargoedUntil2021-02-19
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1055/s-0040-1702920
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record